Skip to main content

Table 1 Clinical characteristics of patients (n = 354)

From: Evaluation of the recurrence pattern of gastric cancer after laparoscopic gastrectomy with D2 lymphadenectomy

Variables Patients with PC (n = 128) Patient without PC (n = 226) All patients (n = 354)
Age (y/o)a 63.0 ± 9.5 62.4 ± 10.8 62.6 ± 10.3
Gender (male:female) 96: 32 148: 78 244: 1110
Body mass index (kg/m2)a 22.4 ± 3.4 21.9 ± 3.1 22.1 ± 3.2
Comorbidity: n (%) 63 (49.2) 111 (49.1) 174 (49.2)
Prior operations: n (%) 14 (10.9) 32 (14.2) 46 (13.0)
ASA: n (%)    
 Class 1 62 (48.4) 110 (48.7) 172 (48.6)
 Class 2 50 (39.1) 96 (42.5) 146 (41.2)
 Class 3 16 (12.5) 20 (8.8) 36 (10.2)
Tumor size (mm)a 48.0 ± 33.0 39.3 ± 24.4 42.4 ± 28.1
Type of resection: n (%)    
 LDG 74 (57.8) 177 (78.3) 251 (70.9)
 LTG 54 (42.2) 49 (21.7) 103 (29.1)
Harvested lymph nodes (n)a 43.8 ± 15.3 44.6 ± 15.9 44.3 ± 15.7
Pathological status (yp/p): n (%)    
 CR 8 (6.3) 0 (0) 8 (2.3)
 T1 24 (18.8) 100 (44.2) 124 (35.1)
 T2 19 (14.8) 40 (17.7) 59 (16.7)
 T3 36 (28.1) 27 (11.9) 63 (17.8)
 T4 41 (32.0) 59 (26.1) 100 (28.2)
Lymph node metastasis (yp/p): n (%)    
 N0 70 (54.7) 130 (57.5) 200 (56.5)
 N1 20 (15.6) 39 (17.3) 59 (16.7)
 N2 20 (15.6) 35 (15.5) 55 (15.5)
 N3 18 (14.1) 22 (9.7) 40 (11.3)
Stage (yp/p): n (%)    
 CR 8 (6.3) 0 (0) 8 (2.3)
 Stage I 36 (28.1) 113 (50.0) 149 (42.1)
 Stage II 43 (33.6) 58 (25.7) 101 (28.5)
 Stage III 41 (32.0) 55 (24.3) 96 (27.1)
Median follow-up period (month) 40.9 45.4 43.8
  1. Values in parentheses are percentages unless otherwise indicated
  2. PC preoperative chemotherapy, CR pathological complete response to PC, ASA American Society of Anesthesiologists, LDG laparoscopic distal gastrectomy, LTG laparoscopic total gastrectomy
  3. aValues expressed as the mean ± SD